Drug Repurposing of Loratadine as a DNMT1 Inhibitor: Comparative Evaluation with Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells. Precis. Med. Com. 2024;4(2):125-137. doi:10.55627/pmc.004.02.1083